UBS AM
TTPH

UBS AM’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

UBS AM’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-575
Closed -$53K – 2647
2016
Q1 		$53K Sell
575
-45
-7% -$4.5K ﹤0.01% 2609
2015
Q4 		$124K Hold
620
– – ﹤0.01% 2644
2015
Q3 		$93K Hold
620
– – ﹤0.01% 2619
2015
Q2 		$588K Buy
620
+150
+32% +$123K ﹤0.01% 1980
2015
Q1 		$344K Buy
470
+25
+6% +$18.8K ﹤0.01% 2182
2014
Q4 		$353K Buy
+445
New +$240K ﹤0.01% 2123

Other funds holding TTPH

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

UBS AM's TTPH Position: Q2 2016 in Review

UBS AM sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q2 2016, closing a stake of 575 shares — an estimated $53K sold.

UBS AM first reported a position in TTPH in Q4 2014 and held it in 6 quarters. The position peaked at $588K in Q2 2015. 91 funds tracked by Wall St. Rank hold TTPH as of Q2 2016.

  • UBS AM reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • UBS AM sold 575 Tetraphase Pharmaceuticals, Inc. shares in Q2 2016, an estimated $53K.
  • UBS AM first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2014 and held it in 6 quarters.
  • UBS AM's Tetraphase Pharmaceuticals, Inc. position peaked at $588K in Q2 2015.
  • 91 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q2 2016.

Based on UBS AM's 13F filing for Q2 2016, filed 9 Aug 2016.